Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company focused on developing transformative therapies for rare diseases, has announced its participation in the Guggenheim SMID Cap Biotech Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company focused on developing transformative therapies for rare diseases, has announced its participation in the Guggenheim SMID Cap Biotech Conference. The conference is scheduled for February 5-6, 2025, in New York City.
The company's management team will be available for one-on-one meetings with investors throughout the conference. Interested investors can arrange meetings through their Guggenheim representatives.
Details
News Market Reaction – RZLT
The recorded move for RZLT in the trading session of this news was +0.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the Guggenheim SMID Cap Biotech Conference, taking place February 5-6, 2025, in New York City.
Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Contact:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.